Project Grant R41AI132012

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $347,608 to Biotherapeutics, Inc. to develop a novel, oral, once-daily, immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) characterize the therapeutic efficacy and route of administration of the drug candidate in mouse models of asthma, and 2) determine the translational ability of the therapeutic...

This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), will support a clinical trial to examine the use of the selective serotonin reuptake inhibitor (SSRI) escitalopram for improving asthma control in adults with frequent asthma exacerbations. The $790,698 award to the University of Texas Southwestern Medical Center will fund a 24-week, randomized, double-blind, placebo-controlled trial of...

This Project Grant award of $1,491,931 from the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research is focused on investigating the immune mechanisms by which GLP-1 receptor agonists can reduce inflammation in both lean and obese patients with asthma. The research aims to identify the cellular targets and anti-inflammatory pathways of GLP-1 signaling in order to inform the clinical repurposing of GLP-1R agonists for asthma...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...

This federal Project Grant award of $231,617 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of California, Davis to investigate the efficacy of inhaled pitavastatin as a novel therapy for the treatment of asthma. The key objectives are to: 1) determine the efficacy of inhaled pitavastatin as a bronchodilator in a rhesus macaque model of airway hyperresponsiveness, and 2) evaluate the...

This federal Project Grant award of $613,934 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research into the role of the aryl hydrocarbon receptor (AhR) signaling pathway in regulating airway smooth muscle responses during inflammation and asthma. The key objectives are to: 1) Determine the mechanisms of AhR expression and regulation in human airway smooth muscle under inflammatory conditions; 2) Investigate...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $207,500 to the University of Southern California to study the role of the MIF/CD74 pathway in group 2 innate lymphoid cells (ILC2) and its impact on airway hyperreactivity and asthma. The key objectives of this 2-year research project are to: 1) Assess the expression patterns of CD74 in the lungs and measure...

This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $636,843 to The Regents of the University of California, San Francisco (UCSF) to conduct research on targeting the stromal niche for tissue-resident lymphocytes in asthma. The research aims to characterize a targetable stromal factor that alters immune cell accumulation in the lung and define the downstream effects on airway epithelial...

This federal Project Grant award for $2,016,357 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Mayo Clinic to investigate the role of Transmembrane Protein 178 (TMEM178) as a novel endogenous inhibitory mechanism in asthma. The research aims to characterize how TMEM178 regulates calcium responses and inflammation in bronchial epithelial cells, and assess the impact of TMEM178 genetic variants on asthma severity. The...